Status:
NOT_YET_RECRUITING
Tofacitinib in Juvenile Idiopathic Arthritis
Lead Sponsor:
Consorci Sanitari de l'Alt Penedès i Garraf
Conditions:
Juvenile Idiopathic Arthritis (JIA)
Eligibility:
All Genders
Up to 18 years
Brief Summary
This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist.
- Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.
- Age under 18 years at the time of the treatment indication with tofacitinib.
- Exclusion criteria:
- Participants diagnosed with any of the following conditions:
- Reactive arthritis
- Arthritis associated with inflammatory bowel disease
- Arthritis associated with another autoimmune disease
Exclusion
Key Trial Info
Start Date :
December 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT07211932
Start Date
December 1 2025
End Date
December 1 2026
Last Update
November 26 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Sant Joan de Déu Barcelona
Barcelona, Barcelona, Spain
2
Corporació Sanitària Parc Taulí de Sabadell
Sabadell, Barcelona, Spain
3
Hospital de Vilafranca
Vilafranca del Penedès, Barceona, Spain, 08720